Coagulum Pyelolithotomy “Revisited” by Laparoscopy: Technique Modification

Borges, Ricardo; Azinhais, P.; Retroz, E.; Temido, Paulo; Pereira, Bruno; Leão, Ricardo; Grenha, V.; Coelho, Hugo; Sousa, Luís; Brandão, Álvaro; Cristo, L.; Sobral, F.

doi:10.1016/j.urology.2012.02.051

Cited by 7 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first one describes using fibrin sealant in 107 cases of tubeless percutaneous nephrolithotomy as a method of obtaining hemostasis in the access tract [ 267 ] with no patients requiring a blood transfusion and with only one pseudoaneurysm requiring selective embolization. The second describes using a laparoscopic coagulum pyelolithotomy employing fibrin sealant to create a colored (methylene blue added) coagulum capable of helping to extract even more stones than originally documented on X-ray studies [ 268 ]. Fibrin sealant has also been used in total or partial nephrectomy including a case report of stopping hematuria from the ureteric remnant endoscopically using fulguration as well as fibrin sealant [ 269 ], a series of patients ( n = 45) in whom autologous fibrin sealant was applied to the resection bed during laparoscopic partial nephrectomy [ 270 ], and another sequential retrospective series of laparoscopic partial nephrectomies [ 271 ] where microporous polysaccharide spheres (MPH, n = 12) or fibrin sealant (historical control, n = 43) was applied to the resection bed finding that mean estimated blood loss was significantly less in the MPH group (25.6 versus 86.3 mL, P = 0.036).…”

Section: Less Frequently Published Clinical Applications Of Fibrinmentioning

confidence: 99%

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

2014

View full text Add to dashboard Cite

Background. Fibrin sealant became the first modern era material approved as a hemostat in the United States in 1998. It is the only agent presently approved as a hemostat, sealant, and adhesive by the Food and Drug Administration (FDA). The product is now supplied as patches in addition to the original liquid formulations. Both laboratory and clinical uses of fibrin sealant continue to grow. The new literature on this material also continues to proliferate rapidly (approximately 200 papers/year). Methods. An overview of current fibrin sealant products and their approved uses and a comprehensive PubMed based review of the recent literature (February 2012, through March 2013) on the laboratory and clinical use of fibrin sealant are provided. Product information is organized into sections based on a classification system for commercially available materials. Publications are presented in sections based on both laboratory research and clinical topics are listed in order of decreasing frequency. Results. Fibrin sealant remains useful hemostat, sealant, and adhesive. New formulations and applications continue to be developed. Conclusions. This agent remains clinically important with the recent introduction of new commercially available products. Fibrin sealant has multiple new uses that should result in further improvements in patient care.

show abstract

Section: Less Frequently Published Clinical Applications Of Fibrinmentioning

confidence: 99%

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

2014

View full text Add to dashboard Cite

show abstract

“…Borges ve ark. 'ları da; fibrin ve trombin karışımından bir koagülüm sayesinde kaliksiyel taşların temizlenebileceğini bildirmişlerdir (25).…”

Section: Böbrek Taşlarıunclassified

Taş Hastalığında Açık ve Laparoskopik Cerrahinin Yeri Var Mı?

Şahin¹,

Tuğcu²

2016

Endouroloji

View full text Add to dashboard Cite

“…Salvado et al 30 described the routine use of a flexible nephroscope inserted laparo scopically during surgery. Borges and colleagues 31 addressed the issue of calyceal stone clearance by creating a stone coagulum using a fibrin and throm bin mixture. Additionally, although experience using laparoscopic pyelolithotomy in the event of staghorn calculi is more limited, Nouralizadeh and coworkers 32 published successful results from 13 such cases.…”

Section: Nature Reviews | Urologymentioning

confidence: 99%

The role of open and laparoscopic stone surgery in the modern era of endourology

Borofsky

Lingeman

2015

Nat Rev Urol

View full text Add to dashboard Cite

Treatment options for kidney stones and ureteral stones have evolved considerably over the past several decades, to the point where almost any stone can now be considered for treatment with a noninvasive or a minimally invasive approach including shock wave lithotripsy, ureteroscopy or percutaneous nephrolithotomy. The safety and morbidity associated with these techniques are favourable relative to traditional open surgical approaches to stone removal. However, they also require unique skillsets, access to instrumentation and relatively high maintenance costs, potentially limiting their use on a global scale. Coincident with the emergence of endourology have been considerable improvements in laparoscopic surgical techniques to the point that nearly any open surgery can be performed in a minimally invasive laparoscopic fashion. Such approaches, including those with robotic assistance, have potential application for the treatment of upper urinary tract stones, particularly in complex senarios as well as in areas where access to endourological instruments might be limited.

show abstract

Coagulum Pyelolithotomy “Revisited” by Laparoscopy: Technique Modification

Cited by 7 publications

References 6 publications

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

Taş Hastalığında Açık ve Laparoskopik Cerrahinin Yeri Var Mı?

The role of open and laparoscopic stone surgery in the modern era of endourology

Contact Info

Product

Resources

About